NO3004079T3 - - Google Patents
Info
- Publication number
- NO3004079T3 NO3004079T3 NO14727562A NO14727562A NO3004079T3 NO 3004079 T3 NO3004079 T3 NO 3004079T3 NO 14727562 A NO14727562 A NO 14727562A NO 14727562 A NO14727562 A NO 14727562A NO 3004079 T3 NO3004079 T3 NO 3004079T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1350685 | 2013-06-04 | ||
PCT/EP2014/061503 WO2014195323A1 (fr) | 2013-06-04 | 2014-06-03 | Composés de pyrimidine et leur utilisation comme modulateurs de la gamma-sécrétase |
Publications (1)
Publication Number | Publication Date |
---|---|
NO3004079T3 true NO3004079T3 (fr) | 2018-06-16 |
Family
ID=50877325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO14727562A NO3004079T3 (fr) | 2013-06-04 | 2014-06-03 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9439904B2 (fr) |
EP (1) | EP3004079B1 (fr) |
JP (1) | JP6368777B2 (fr) |
CN (1) | CN105263923B (fr) |
DK (1) | DK3004079T3 (fr) |
ES (1) | ES2665421T3 (fr) |
NO (1) | NO3004079T3 (fr) |
PL (1) | PL3004079T3 (fr) |
WO (1) | WO2014195323A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018007331A1 (fr) * | 2016-07-08 | 2018-01-11 | F. Hoffmann-La Roche Ag | Dérivés fusionnés de pyrimidine |
CN108191776A (zh) * | 2018-01-22 | 2018-06-22 | 无锡富泽药业有限公司 | 一种尿嘧啶的绿色生产工艺 |
WO2020247707A1 (fr) * | 2019-06-05 | 2020-12-10 | Chunyu Wang | SYSTÈME ET PROCÉDÉ D'INHIBITION DE LA PRODUCTION DE γ-SÉCRÉTASE ET DE PEPTIDES β-AMYLOÏDES |
CN110372603A (zh) * | 2019-06-24 | 2019-10-25 | 南京普锐达医药科技有限公司 | 一种2-氯-5-氟-6-乙基嘧啶的合成方法 |
US11578061B2 (en) | 2021-03-23 | 2023-02-14 | Halia Therapeutics, Inc. | Inhibitors of LRRK2 kinase |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002528499A (ja) * | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | Impdh酵素のインヒビターであるアミノ核誘導化合物 |
ITMI20030312A1 (it) | 2003-02-21 | 2004-08-22 | Chiesi Farma Spa | Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer. |
US20080153817A1 (en) | 2003-08-07 | 2008-06-26 | Dirk Beher | Treatment for Alzheimer's Disease and Related Conditions |
JP2007513128A (ja) | 2003-12-03 | 2007-05-24 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病および関連状態の治療に有用な1−アルキル−3−チオ置換インドール−2−アルキン酸 |
EP1757591A4 (fr) | 2004-05-26 | 2010-05-05 | Eisai R&D Man Co Ltd | Composé de cinnamide |
EP1951684B1 (fr) * | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Inhibiteurs de kinase de type biaryl-méta-pyrimidine |
WO2007125364A1 (fr) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Limited | Pipéridines et composés apparentés pour traiter la maladie d'alzheimer |
EP2019093A4 (fr) | 2006-05-19 | 2011-02-23 | Eisai R&D Man Co Ltd | Dérivé de cinnamide de type urée |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
EP2117311A4 (fr) | 2007-02-08 | 2011-05-11 | Merck Sharp & Dohme | Agents thérapeutiques |
AU2008216842A1 (en) | 2007-02-12 | 2008-08-21 | Merck Sharp & Dohme Corp. | Piperidine derivatives |
WO2008099210A2 (fr) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées |
US8242150B2 (en) | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
MX2010001506A (es) | 2007-08-06 | 2010-03-10 | Schering Corp | Moduladores de gamma secretasa. |
ES2375919T3 (es) | 2008-01-11 | 2012-03-07 | F. Hoffmann-La Roche Ag | Moduladores de beta-amiloide. |
BRPI0907577A2 (pt) * | 2008-02-22 | 2015-07-21 | Hoffmann La Roche | Moduladores para amiloide beta |
JP5502089B2 (ja) * | 2008-10-09 | 2014-05-28 | エフ.ホフマン−ラ ロシュ アーゲー | アミロイドβのモジュレーター |
WO2010053438A1 (fr) | 2008-11-06 | 2010-05-14 | Astrazeneca Ab | Modulateurs de la protéine β-amyloïde |
CN102209537A (zh) | 2008-11-10 | 2011-10-05 | 弗·哈夫曼-拉罗切有限公司 | 杂环γ分泌酶调节剂 |
TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
UY32622A (es) | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
AP2011006034A0 (en) | 2009-07-15 | 2011-12-31 | Janssen Pharmaceuticals Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators. |
TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
ES2512840T3 (es) | 2010-01-15 | 2014-10-24 | Janssen Pharmaceuticals, Inc. | Derivados de triazol bicíclicos sustituidos novedosos como moduladores de gamma-secretasa |
US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
TW201206946A (en) | 2010-07-15 | 2012-02-16 | Bristol Myers Squibb Co | Compounds for the reduction of beta-amyloid production |
-
2014
- 2014-06-03 CN CN201480032083.0A patent/CN105263923B/zh not_active Expired - Fee Related
- 2014-06-03 JP JP2016517275A patent/JP6368777B2/ja not_active Expired - Fee Related
- 2014-06-03 DK DK14727562.2T patent/DK3004079T3/en active
- 2014-06-03 WO PCT/EP2014/061503 patent/WO2014195323A1/fr active Application Filing
- 2014-06-03 EP EP14727562.2A patent/EP3004079B1/fr active Active
- 2014-06-03 PL PL14727562T patent/PL3004079T3/pl unknown
- 2014-06-03 ES ES14727562.2T patent/ES2665421T3/es active Active
- 2014-06-03 NO NO14727562A patent/NO3004079T3/no unknown
- 2014-06-03 US US14/895,528 patent/US9439904B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3004079A1 (fr) | 2016-04-13 |
JP6368777B2 (ja) | 2018-08-01 |
DK3004079T3 (en) | 2018-04-16 |
US9439904B2 (en) | 2016-09-13 |
WO2014195323A1 (fr) | 2014-12-11 |
ES2665421T3 (es) | 2018-04-25 |
CN105263923B (zh) | 2017-06-23 |
CN105263923A (zh) | 2016-01-20 |
JP2016520637A (ja) | 2016-07-14 |
PL3004079T3 (pl) | 2018-07-31 |
EP3004079B1 (fr) | 2018-01-17 |
US20160129002A1 (en) | 2016-05-12 |